Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo

Human Gene Therapy Methods

Volumn 26, Issue 6, 2015, Pages 211-220

  Li, Baozheng ^a   Ma, Wenqin ^a   Ling, Chen ^a,b,c   Van Vliet, Kim ^d   Huang, Lin Ya ^d   Agbandje McKenna, Mavis ^b,c,d   Srivastava, Arun ^a,b,c,d,e,f   Aslanidi, George V ^a,b,c  

^a Division of Cellular and Molecular Therapy   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Genetics Institute   (United States)

^d Department of Biochemistry and Molecular Biology ^*  (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f Cancer and Genetics Research Complex   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; LYSINE; PARVOVIRUS VECTOR; PROTEASOME; UBIQUITIN; CAPSID PROTEIN;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LIVER CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; SITE DIRECTED MUTAGENESIS; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; CELL CULTURE; CELL LINE; CHEMISTRY; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; REPORTER GENE; TRANSGENE;

ANIMALS; CAPSID PROTEINS; CELL LINE; CELLS, CULTURED; DEPENDOVIRUS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HEPATOCYTES; HUMANS; LYSINE; MICE; MUTAGENESIS, SITE-DIRECTED; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84949666934     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2015.115     Document Type: Article

References (39)

1. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-245.
2. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat Rev Genet 2011;12:341-355.
3. Mingozzi F, High KA. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 2013;122:23-36.
4. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
5. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-422.
6. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009;119:1688-1695.
7. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-2365.
8. Nathwani AC, Reiss UM, Tuddenham EG, et al. Longterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371:1994-2004.
9. Wang LN, Wang Y, Lu Y, et al. Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. J Integr Med 2014;12:20-34.
10. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007;15:1323-1330.
11. Zhong L, Li B, Jayandharan G, et al. Tyrosinephosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008;381:194-202.
12. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008;105:7827-7832.
13. Aslanidi GV, Rivers AE, Ortiz L, et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: The final threshold? PLoS One 2013;8:e59142.
14. Aslanidi GV, Rivers AE, Ortiz L, et al. High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine 2012;30:3908-3917.
15. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012;81:203-229.
16. Markusic DM, Herzog RW, Aslanidi GV, et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 2010;18:2048-2056.
17. Malato Y, Naqvi S, Schurmann N, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 2011;121:4850-4860.
18. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79:214-224.
19. Mondal J, Bishayee K, Panigrahi AK, et al. Low doses of ethanolic extract of Boldo (Peumus boldus) can ameliorate toxicity generated by cisplatin in normal liver cells of mice in vivo and in WRL-68 cells in vitro, but not in cancer cells in vivo or in vitro. J Integr Med 2014;12:425-438.
20. Liu Y, Joo KI, Wang P. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 2013;20: 308-317.
21. Liu Y, Kim YJ, Ji M, et al. Enhancing gene delivery of adeno-associated viruses by cellpermeable peptides. Mol Ther Methods Clin Dev 2014;1:12.
22. Gu Y, Lin S, Li JL, et al. Altered LKB1/CREBregulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012;31:469-479.
23. Zhang YH, Wang Y, Yusufali AH, et al. Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. J Integr Med 2014;12:483-494.
24. Emsley P, Lohkamp B, Scott WG, et al. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486-501.
25. Carrillo-Trip M, Shepherd CM, Borelli IA, et al. VIPER2: an enhanced and web API enabled relational database for structural virology. Nucl Acids Res 2009;37:D436-D442.
26. Bramucci E, Paiardini A, Bossa F, et al. PyMod: Sequence similarity searches, multiple sequencestructure alignments, and homology modeling within PyMOL. BMC Bioinform 2012;13 Suppl 4:S2.
27. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002;99: 10405-10410.
28. Gabriel N, Hareendran S, Sen D, et al. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum Gene Ther Methods 2013;24:80-93.
29. Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-1080.
30. Ling C, Lu Y, Kalsi JK, et al. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 2010;21:1741-1747.
31. Song L, Kauss MA, Kopin E, et al. Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy 2013;15:986-998.
32. Sen D, Gadkari RA, Sudha G, et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 2013; 24:104-116.
33. Qiao C, Li C, Zhao C, et al. K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo. Hum Gene Ther Methods 2014;25:33-39.
34. Hansen J, Qing K, Kwon HJ, et al. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000;74:992-996.
35. Yan Z, Zak R, Luxton GW, et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002;76:2043-2053.
36. Halder S, Ng R, Agbandje-McKenna M. Parvoviruses: structure and infection. Future Virol 2012;7:253-278.
37. Lochrie MA, Tatsuno GP, Christie B, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 2006;80:821-834.
38. Ojano-Dirain C, Glushakova LG, Zhong L, et al. An animal model of PDH deficiency using AAV8-siRNA vector-mediated knockdown of pyruvate dehydrogenase E1alpha. Mol Genet Metab 2010; 101:183-191.
39. Finn JD, Hui D, Downey HD, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 2010;18:135-142.